Lebre Maria Cristina, Tak Paul Peter
Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Hum Immunol. 2009 May;70(5):321-4. doi: 10.1016/j.humimm.2009.02.006. Epub 2009 Feb 21.
Dendritic cells (DC) comprise a complex network of heterogeneous antigen-presenting cells (APC) that are critical not only to the initiation and regulation of adaptive immunity (Th1/Th2/Th17 responses), but also to the maintenance of both central and peripheral tolerance (regulatory T cells, peripheral T-cell deletion). Previous work has clearly indicated a role for DC subsets in the pathogenesis of rheumatoid arthritis (RA). Therefore, utilizing these cells as therapeutic agents could be beneficial in the treatment of RA. However, it remains unclear which DC should be used for tolerance-inducing immunotherapy: myeloid, plasmacytoid, or both? This review summarizes the data obtained thus far concerning the functional characterization of several DC subsets in human RA and accordingly explores their potential use for immunotherapy.
树突状细胞（DC）构成了一个由异质性抗原呈递细胞（APC）组成的复杂网络，这些细胞不仅对适应性免疫（Th1/Th2/Th17反应）的启动和调节至关重要，而且对维持中枢和外周耐受性（调节性T细胞、外周T细胞缺失）也至关重要。先前的研究清楚地表明DC亚群在类风湿性关节炎（RA）发病机制中的作用。因此，将这些细胞用作治疗剂可能对RA的治疗有益。然而，目前尚不清楚应该使用哪种DC进行诱导耐受性免疫治疗：髓样DC、浆细胞样DC，还是两者都用？这篇综述总结了迄今为止获得的有关人类RA中几种DC亚群功能特征的数据，并据此探讨了它们在免疫治疗中的潜在用途。
